Pomalidomide triplet significantly extends PFS in R/R MM

Print Friendly, PDF & Email


ASCO 2018 attendees at a poster session
Photo by © ASCO/Scott Morgan 2018
The addition of pomalidomide to bortezomib and low‐dose dexamethasone (PVd) significantly improves progression-free survival (PFS) in lenalidomide-exposed patients with relapsed or refractory (R/R) multiple myeloma (MM). Up until now, pomalidomide and dexamethasone (Pd) had been the only therapy investigated exclusively after lenalidomide... [Read Article]
Print Friendly, PDF & Email

FDA approves first biosimilar pegfilgrastim

Print Friendly, PDF & Email


Vials and a syringe
The US Food and Drug Association (FDA) has approved pegfilgrastim-jmdb (Fulphila™) as the first biosimilar to Neulasta®. The agents reduce the risk of infection or the duration of febrile neutropenia in patients treated with immunosuppressive chemotherapy for non-myeloid hematologic malignancies. The FDA approved Fulphila based on evidence that included extensive... [Read Article]
Print Friendly, PDF & Email

Liquid biopsies may be the future in managing MM patients

Print Friendly, PDF & Email


Blood sample collection
Photo by Juan D. Alfonso
Scientists from the Dana-Farber Cancer Institute and the Broad Institute in Boston, Massachusetts, have shown that in multiple myeloma (MM), liquid biopsies provide similar genetic information as tumor biopsies. Unlike tumor biopsies, liquid biopsies are noninvasive and, in the future, may offer a cost-effective way of following... [Read Article]
Print Friendly, PDF & Email

Study of daratumamb with anti-PD-1 antibody in MM discontinued

Print Friendly, PDF & Email


Daratumumab (Darzalex)
Photo courtesy of Janssen
Janssen is discontinuing the phase 1 MMY2036 study of daratumumab in combination with the anti PD-1 antibody JNJ-63723283 in patients with multiple myeloma (MM). Janssen made the decision based on a Data Monitoring Committee review of Genmab’s phase 1b/2 study (LUC2001) of daratumumab plus the anti-PD-L1 antibody atezolizumab... [Read Article]
Print Friendly, PDF & Email